Bayer starts Phase II trial of investigational GIRK4 inhibitor in atrial fibrillation
Bayer initiated a Phase II study of an investigational GIRK4 inhibitor in patients with atrial fibrillation.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.